Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

Phase

N/A

Condition

Pregnancy

Pregnancy Complications

Treatment

Epidiolex

Clinical Study ID

NCT06113237

GWEP21095

Female

Study Summary

The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients with exposure to at least 1 dose of Epidiolex/Epidyolex during the 13 daysprior to their LMP or at any time during pregnancy.
Verbal or written informed consent to participate

Exclusion

Exclusion criteria:

Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.

Study Design